Paratek Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PRTK)

$17.80 0.35 (2.01 %)
(As of 12/17/2017 08:43 AM ET)
Previous Close$17.80
Today's Range$17.40 - $17.90
52-Week Range$13.15 - $29.00
Volume533,949 shs
Average Volume357,942 shs
Market Capitalization$497.35 million
P/E RatioN/A
Dividend YieldN/A
Beta0.7

About Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals logoParatek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PRTK
CUSIP89354M10
Phone617-807-6600

Debt

Debt-to-Equity Ratio0.49%
Current Ratio10.53%
Quick Ratio10.53%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$30,000.00
Price / Sales16,577.73
Cash FlowN/A
Price / CashN/A
Book Value$3.16 per share
Price / Book5.63

Profitability

Trailing EPS($3.73)
Net Income$-111,630,000.00
Net Margins-1,236.38%
Return on Equity-100.84%
Return on Assets-58.71%

Miscellaneous

Employees50
Outstanding Shares27,940,000

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) issued its quarterly earnings results on Monday, May, 2nd. The specialty pharmaceutical company reported ($1.77) EPS for the quarter, missing analysts' consensus estimates of ($1.25) by $0.52. Paratek Pharmaceuticals had a negative net margin of 1,236.38% and a negative return on equity of 100.84%. View Paratek Pharmaceuticals' Earnings History.

Where is Paratek Pharmaceuticals' stock going? Where will Paratek Pharmaceuticals' stock price be in 2017?

7 analysts have issued 12-month price objectives for Paratek Pharmaceuticals' shares. Their predictions range from $30.00 to $56.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $42.71 in the next twelve months. View Analyst Ratings for Paratek Pharmaceuticals.

What are Wall Street analysts saying about Paratek Pharmaceuticals stock?

Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (11/1/2017)
  • 2. Cantor Fitzgerald analysts commented, "There has been a lot of interest this morning in headlines stating that PRTK is considering all of its strategic options including a sale of the company. We have always believed that PRTK is a very interesting asset in a consolidating space where many antibiotic companies have been taken out. Please see our previously published research on PRTK for more details on our thoughts here. With positive Phase 3 data, PRTK is at the inflection point where potential acquirors would take a look since the asset has been de-risked." (8/23/2017)
  • 3. Robert W. Baird analysts commented, "Though sarecycline is not a key driver, it provides a potential source of non-dilutive financing and further validates Paratek's ability to develop a once daily, well tolerated, tetracycline-derived antibiotic. Looking ahead, we expect continued momentum with focus on key upcoming data readouts from two Phase 3 studies of omadacycline in 2Q17, supporting filing in 1H18, and we reiterate our Outperform rating." (3/27/2017)

Who are some of Paratek Pharmaceuticals' key competitors?

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the folowing people:

  • Michael F. Bigham CPA, Chairman of the Board, Chief Executive Officer (Age 59)
  • Evan Loh M.D., President, Chief Operating Officer, Chief Medical Officer, Director (Age 58)
  • Douglas W. Pagan, Chief Financial Officer (Age 45)
  • William M. Haskel, Senior Vice President, General Counsel, Corporate Secretary (Age 56)
  • Jeanne Jew, Senior Vice President - Business Development
  • Evan Tzanis, Senior Vice President - Clinical Development and Clinical Operations
  • Adam Woodrow, Vice President and Chief Commercial Officer (Age 50)
  • Thomas John Dietz, Independent Director (Age 53)
  • Timothy R. Franson M.D., Independent Director (Age 65)
  • Richard J. Lim, Independent Director (Age 45)

Who owns Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Alyeska Investment Group L.P. (3.28%), Pictet Asset Management Ltd. (2.38%), C WorldWide Group Holding A S (2.32%), General American Investors Co. Inc. (1.25%), Commonwealth of Pennsylvania Public School Empls Retrmt SYS (1.23%) and Royce & Associates LP (1.05%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Fund Iv LP Omega and Michael Bigham. View Institutional Ownership Trends for Paratek Pharmaceuticals.

Who sold Paratek Pharmaceuticals stock? Who is selling Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Roumell Asset Management LLC, EAM Investors LLC, Candriam Luxembourg S.C.A., JPMorgan Chase & Co., Axiom International Investors LLC DE, New York State Common Retirement Fund and California State Teachers Retirement System. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.

Who bought Paratek Pharmaceuticals stock? Who is buying Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Commonwealth of Pennsylvania Public School Empls Retrmt SYS, Pictet Asset Management Ltd., Davidson Kempner Capital Management LP, Highbridge Capital Management LLC, C WorldWide Group Holding A S, Omni Partners LLP and Columbus Circle Investors. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.

How do I buy Paratek Pharmaceuticals stock?

Shares of Paratek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of Paratek Pharmaceuticals stock can currently be purchased for approximately $17.80.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $497.35 million and generates $30,000.00 in revenue each year. The specialty pharmaceutical company earns $-111,630,000.00 in net income (profit) each year or ($3.73) on an earnings per share basis. Paratek Pharmaceuticals employs 50 workers across the globe.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]


MarketBeat Community Rating for Paratek Pharmaceuticals (PRTK)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  395
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Paratek Pharmaceuticals (NASDAQ:PRTK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.113.113.113.11
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $41.56$41.56$40.89$38.22
Price Target Upside: 85.93% upside85.93% upside68.61% upside78.61% upside

Paratek Pharmaceuticals (NASDAQ:PRTK) Consensus Price Target History

Price Target History for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ:PRTK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/24/2017Robert W. BairdReiterated RatingBuy$40.00N/AView Rating Details
10/24/2017GuggenheimInitiated CoverageBuy$44.00N/AView Rating Details
10/17/2017Cantor FitzgeraldSet Price TargetBuy$50.00N/AView Rating Details
8/24/2017Raymond James FinancialReiterated RatingStrong-Buy$36.00MediumView Rating Details
7/18/2017HC WainwrightBoost Price TargetPositive -> Buy$36.00 -> $43.00HighView Rating Details
4/4/2017BTIG ResearchBoost Price TargetBuy$47.00 -> $56.00MediumView Rating Details
4/3/2017WedbushReiterated RatingOutperform -> Outperform$30.00HighView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$23.00N/AView Rating Details
6/17/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$46.00 -> $52.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Paratek Pharmaceuticals (NASDAQ:PRTK) Earnings History and Estimates Chart

Earnings by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ PRTK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017($0.89)($0.64)$7.50 million$7.51 millionViewListenView Earnings Details
5/4/2017Q1 2017($1.20)($1.14)$0.02 millionViewListenView Earnings Details
3/2/2017Q4 2016($1.33)($1.17)$0.03 millionViewListenView Earnings Details
11/2/2016($1.38)($1.04)ViewN/AView Earnings Details
5/2/2016($1.25)($1.77)ViewN/AView Earnings Details
2/23/2016Q4($1.18)($1.20)ViewListenView Earnings Details
11/12/2015Q315($0.91)($1.33)ViewListenView Earnings Details
8/5/2015Q215($0.75)($0.94)$3.62 billionViewN/AView Earnings Details
4/2/2015Q1($2.16)($0.74)$0.13 million$4.00 millionViewN/AView Earnings Details
5/5/2014($0.18)($0.15)$0.42 millionViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.29)$0.50 million$0.32 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.42)($0.56)ViewN/AView Earnings Details
11/12/2012Q312$0.06$0.25$8.37 million$10.44 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Paratek Pharmaceuticals (NASDAQ:PRTK) Earnings Estimates

2017 EPS Consensus Estimate: ($3.61)
2018 EPS Consensus Estimate: ($3.69)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.15)($1.15)($1.15)
Q2 20171($0.79)($0.79)($0.79)
Q3 20172($0.92)($0.87)($0.90)
Q4 20172($0.88)($0.67)($0.78)
Q1 20182($0.95)($0.86)($0.91)
Q2 20182($1.02)($0.89)($0.96)
Q3 20182($1.26)($0.48)($0.87)
Q4 20182($1.19)($0.73)($0.96)
(Data provided by Zacks Investment Research)

Dividends

Paratek Pharmaceuticals (NASDAQ:PRTK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/14/2014special$1.336/4/20145/26/20146/3/2014
(Data available from 1/1/2013 forward)

Insider Trades

Paratek Pharmaceuticals (NASDAQ PRTK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 84.30%
Insider Trades by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)
Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ PRTK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Adam WoodrowVPSell3,800$23.58$89,604.00View SEC Filing  
7/5/2017Douglas W PaganCFOSell4,139$23.58$97,597.62View SEC Filing  
7/5/2017Evan LohCOOSell4,351$23.58$102,596.58View SEC Filing  
7/5/2017Michael BighamChairmanSell5,075$23.58$119,668.50View SEC Filing  
6/19/2017Douglas W PaganCFOSell4,595$25.00$114,875.00View SEC Filing  
2/6/2017Douglas W PaganCFOSell3,405$15.09$51,381.45View SEC Filing  
2/6/2017Evan LohCOOSell3,106$15.09$46,869.54View SEC Filing  
2/6/2017Michael BighamChairmanSell5,000$15.09$75,450.00View SEC Filing  
6/27/2016Fund Iv L.P. OmegaMajor ShareholderBuy461,538$13.00$5,999,994.00View SEC Filing  
6/23/2016Michael BighamCEOBuy20,000$13.45$269,000.00View SEC Filing  
12/11/2015Evan LohCMOBuy2,300$16.87$38,801.00View SEC Filing  
5/29/2015Hbm Healthcare Investments (CaMajor ShareholderSell20,580$30.75$632,835.00View SEC Filing  
12/13/2013Roumell Asset Management, Llcmajor shareholderSell1,470$3.54$5,203.80View SEC Filing  
12/11/2013Roumell Asset Management, Llcmajor shareholderSell10,490$3.55$37,239.50View SEC Filing  
12/6/2013Roumell Asset Management, Llcmajor shareholderSell8,710$3.54$30,833.40View SEC Filing  
12/4/2013Roumell Asset Management, Llcmajor shareholderSell7,120$3.50$24,920.00View SEC Filing  
11/20/2013Roumell Asset Management, Llcmajor shareholderSell10,040$3.57$35,842.80View SEC Filing  
11/12/2013Roumell Asset Management, Llcmajor shareholderSell7,190$3.53$25,380.70View SEC Filing  
11/7/2013Roumell Asset Management, Llcmajor shareholderSell4,960$3.61$17,905.60View SEC Filing  
10/30/2013Roumell Asset Management, LlcMajor ShareholderSell7,020$3.69$25,903.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Paratek Pharmaceuticals (NASDAQ PRTK) News Headlines

Source:
DateHeadline
Paratek Pharmaceuticals Inc (PRTK) Given Consensus Recommendation of "Buy" by AnalystsParatek Pharmaceuticals Inc (PRTK) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 14 at 3:54 AM
$5.00 Million in Sales Expected for Paratek Pharmaceuticals, Inc. (PRTK) This Quarter$5.00 Million in Sales Expected for Paratek Pharmaceuticals, Inc. (PRTK) This Quarter
www.americanbankingnews.com - December 4 at 10:06 AM
Paratek Pharmaceuticals (PRTK) Lowered to "Strong Sell" at BidaskClubParatek Pharmaceuticals (PRTK) Lowered to "Strong Sell" at BidaskClub
www.americanbankingnews.com - December 2 at 11:54 AM
Paratek Pharmaceuticals, Inc. (PRTK) Given Average Recommendation of "Buy" by BrokeragesParatek Pharmaceuticals, Inc. (PRTK) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 19 at 3:44 AM
 Analysts Expect Paratek Pharmaceuticals, Inc. (PRTK) to Announce -$0.75 EPS Analysts Expect Paratek Pharmaceuticals, Inc. (PRTK) to Announce -$0.75 EPS
www.americanbankingnews.com - November 14 at 5:14 AM
Brokers Issue Forecasts for Paratek Pharmaceuticals, Inc.s FY2017 Earnings (PRTK)Brokers Issue Forecasts for Paratek Pharmaceuticals, Inc.'s FY2017 Earnings (PRTK)
www.americanbankingnews.com - November 13 at 2:34 AM
FY2017 EPS Estimates for Paratek Pharmaceuticals, Inc. (PRTK) Raised by AnalystFY2017 EPS Estimates for Paratek Pharmaceuticals, Inc. (PRTK) Raised by Analyst
www.americanbankingnews.com - November 13 at 2:34 AM
Paratek Pharmaceuticals, Inc. (PRTK) Expected to Earn FY2021 Earnings of $0.30 Per ShareParatek Pharmaceuticals, Inc. (PRTK) Expected to Earn FY2021 Earnings of $0.30 Per Share
www.americanbankingnews.com - November 10 at 8:11 PM
First Week Of November 17th Options Trading For Paratek Pharmaceuticals (PRTK)First Week Of November 17th Options Trading For Paratek Pharmaceuticals (PRTK)
www.thestreet.com - November 9 at 11:56 AM
Paratek Pharmaceuticals Inc to Host Earnings CallParatek Pharmaceuticals Inc to Host Earnings Call
finance.yahoo.com - November 9 at 11:56 AM
Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018
finance.yahoo.com - November 9 at 11:56 AM
Paratek reports 3Q lossParatek reports 3Q loss
finance.yahoo.com - November 9 at 11:56 AM
Edited Transcript of PRTK earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of PRTK earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 11:56 AM
CAM Group Holding A Buys Insmed Inc, Zimmer Biomet Holdings Inc, Vertex Pharmaceuticals Inc, ...CAM Group Holding A Buys Insmed Inc, Zimmer Biomet Holdings Inc, Vertex Pharmaceuticals Inc, ...
www.nasdaq.com - November 7 at 9:03 AM
Paratek Pharmaceuticals, Inc. (PRTK) Lifted to Hold at Zacks Investment ResearchParatek Pharmaceuticals, Inc. (PRTK) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - November 1 at 6:34 AM
Paratek For The Layman - Seeking AlphaParatek For The Layman - Seeking Alpha
seekingalpha.com - October 27 at 11:31 AM
These Pharma Executives Are Showing Their CardsThese Pharma Executives Are Showing Their Cards
finance.yahoo.com - October 27 at 11:31 AM
Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017
finance.yahoo.com - October 25 at 9:22 AM
Paratek Pharmaceuticals, Inc. (PRTK) Given Consensus Rating of "Buy" by AnalystsParatek Pharmaceuticals, Inc. (PRTK) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - October 25 at 4:45 AM
Robert W. Baird Reiterates "Buy" Rating for Paratek Pharmaceuticals, Inc. (PRTK)Robert W. Baird Reiterates "Buy" Rating for Paratek Pharmaceuticals, Inc. (PRTK)
www.americanbankingnews.com - October 24 at 4:50 PM
Oversold Conditions For Paratek Pharmaceuticals (PRTK)Oversold Conditions For Paratek Pharmaceuticals (PRTK)
www.thestreet.com - October 19 at 7:46 AM
Paratek Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PRTK) : October 18, 2017Paratek Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PRTK) : October 18, 2017
finance.yahoo.com - October 19 at 7:46 AM
Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PRTK-US : October 17, 2017Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : PRTK-US : October 17, 2017
finance.yahoo.com - October 17 at 4:15 PM
Paratek Pharmaceuticals, Inc. (PRTK) Given a $50.00 Price Target at Cantor FitzgeraldParatek Pharmaceuticals, Inc. (PRTK) Given a $50.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - October 17 at 3:32 PM
Zacks Investment Research Lowers Paratek Pharmaceuticals, Inc. (PRTK) to SellZacks Investment Research Lowers Paratek Pharmaceuticals, Inc. (PRTK) to Sell
www.americanbankingnews.com - October 11 at 10:20 AM
Todays Research Reports on Stocks to Watch: Paratek Pharmaceuticals and 22nd Century GroupToday's Research Reports on Stocks to Watch: Paratek Pharmaceuticals and 22nd Century Group
finance.yahoo.com - October 10 at 2:38 AM
Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid ConditionsConsistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions
finance.yahoo.com - October 8 at 5:10 AM
Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant BacteriaPhase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria
finance.yahoo.com - October 8 at 5:10 AM
Paratek Pharma shares surge 6% on late-stage results for antibioticParatek Pharma shares surge 6% on late-stage results for antibiotic
finance.yahoo.com - October 8 at 5:10 AM
Paratek Pharmaceuticals (PRTK) Says Phase 3 Optic Study Microbiology Data Shows Omadacycline has Potent In vitro ... - StreetInsider.comParatek Pharmaceuticals (PRTK) Says Phase 3 Optic Study Microbiology Data Shows Omadacycline has Potent In vitro ... - StreetInsider.com
www.streetinsider.com - October 7 at 7:34 AM
Paratek Pharma shares surge 6% on late-stage results for antibiotic - MarketWatchParatek Pharma shares surge 6% on late-stage results for antibiotic - MarketWatch
www.marketwatch.com - October 7 at 7:34 AM
Major Biotech, Pharma and FDA Catalysts Coming in OctoberMajor Biotech, Pharma and FDA Catalysts Coming in October
247wallst.com - September 30 at 9:53 AM
Paratek Pharmaceuticals, Inc. (PRTK) Given Average Rating of "Buy" by AnalystsParatek Pharmaceuticals, Inc. (PRTK) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - September 30 at 7:08 AM
Paratek Pharmaceuticals (PRTK) Presents At Ladenburg Thalmann 2017 Healthcare Conference - SlideshowParatek Pharmaceuticals (PRTK) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 4:23 PM
Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017 - GlobeNewswire (press release)Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017 - GlobeNewswire (press release)
globenewswire.com - September 26 at 7:05 PM
Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017
finance.yahoo.com - September 25 at 12:29 PM
Head-To-Head Contrast: Paratek Pharmaceuticals (PRTK) & Its PeersHead-To-Head Contrast: Paratek Pharmaceuticals (PRTK) & Its Peers
www.americanbankingnews.com - September 24 at 2:18 AM
Contrasting Auris Medical Holding AG (EARS) & Paratek Pharmaceuticals (PRTK)Contrasting Auris Medical Holding AG (EARS) & Paratek Pharmaceuticals (PRTK)
www.americanbankingnews.com - September 23 at 8:30 PM
Parateks omadacycline granted additional QIDP status in US - Seeking AlphaParatek's omadacycline granted additional QIDP status in US - Seeking Alpha
seekingalpha.com - September 23 at 12:38 AM
Paratek Pharmaceuticals, Inc. (PRTK) Stock Rating Reaffirmed by Cantor FitzgeraldParatek Pharmaceuticals, Inc. (PRTK) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - September 22 at 3:50 PM
Omadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract InfectionsOmadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract Infections
finance.yahoo.com - September 22 at 2:24 PM
Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017
finance.yahoo.com - September 20 at 7:57 AM
 Brokerages Expect Paratek Pharmaceuticals, Inc. (PRTK) Will Announce Earnings of -$0.93 Per Share Brokerages Expect Paratek Pharmaceuticals, Inc. (PRTK) Will Announce Earnings of -$0.93 Per Share
www.americanbankingnews.com - September 17 at 2:28 AM
Paratek Pharmaceuticals (PRTK) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowParatek Pharmaceuticals (PRTK) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 8:00 AM
Paratek Pharmaceuticals, Inc. (PRTK) Receives Consensus Recommendation of "Buy" from AnalystsParatek Pharmaceuticals, Inc. (PRTK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 5 at 6:50 AM
Paratek Announces Inducement Grants under NASDAQ Listing Rule ... - GlobeNewswire (press release)Paratek Announces Inducement Grants under NASDAQ Listing Rule ... - GlobeNewswire (press release)
globenewswire.com - September 2 at 7:44 AM
Here's Why Paratek Pharmaceuticals Soared as Much as 37% TodayHere's Why Paratek Pharmaceuticals Soared as Much as 37% Today
finance.yahoo.com - August 24 at 11:23 AM
Todays Research Reports on Stocks to Watch: Paratek Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc.Today's Research Reports on Stocks to Watch: Paratek Pharmaceuticals Inc. and Ultragenyx Pharmaceutical Inc.
finance.yahoo.com - August 24 at 11:23 AM
Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PRTK-US : August 24, 2017Paratek Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PRTK-US : August 24, 2017
finance.yahoo.com - August 24 at 11:23 AM
Paratek Pharmaceuticals, Inc. (PRTK) Catches Eye: Stock Up 27.3%Paratek Pharmaceuticals, Inc. (PRTK) Catches Eye: Stock Up 27.3%
finance.yahoo.com - August 24 at 11:23 AM

SEC Filings

Paratek Pharmaceuticals (NASDAQ:PRTK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Paratek Pharmaceuticals (NASDAQ:PRTK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Paratek Pharmaceuticals (NASDAQ PRTK) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.